BB Investment Banking Healthcare
Do you guys know which of the BB offices works on the most number of healthcare, pharma, biotech deals? Especially for GS, MS, and JP? Thanks
Do you guys know which of the BB offices works on the most number of healthcare, pharma, biotech deals? Especially for GS, MS, and JP? Thanks
+178 | BOFA ALREADY TRYING TO COVER UP THEIR TRACKS | 27 | 14m | |
+152 | Investment Banking US League Table YTD 2024 (FactSet) | 84 | 10h | |
+143 | Big Layoff at Barclays - 5/1/24 | 79 | 13m | |
+87 | “Americans just work harder” | 53 | 23h | |
+83 | Would comitting to ATL İB be stupid? Please give feedback. | 45 | 3d | |
+68 | Sleeping on Jefferies??? | 33 | 3s | |
+66 | A shitter's comprehensive guide to sophomore year recruiting | 7 | 19h | |
+59 | NEED NY RESTAURANT RECOMMENDATIONS | 38 | 3d | |
+58 | What's up with RBC nowadays? | 24 | 18h | |
+50 | 5-Step (Borderline Psycho) Pre-Superday Routine I Used to Land Every IB Internship Offer | 4 | 2d |
Career Resources
"healthcare" is a giant industry ... saying you work in healthcare is kind of like saying you work in finance. It's sufficient for outsiders, but ambiguous for people familiar with the space ...
I like to break healthcare into the following high-level sectors:
Facilities and providers Medical equipment and devices Bio-tech and pharma
you specifically mentioned bio-tech/pharma, so I ran a quick cap iq screen of closed transactions in this space over the past two years ... I will PM you the results
couldn't figure out how to PM an attachment so i created a topic with the excel file:
http://www.wallstreetoasis.com/forums/re-bb-investment-banking-healthca…
Healthcare Investment Banking BB bank (Originally Posted: 06/21/2012)
Hi, Am new to WSO. Have interned in a top 10 UK bank and am now looking to move to a BB in the healthcare team. Am trying to brush up on healthcare specific valuation methods - specifically for:
1). Pharma (am thinking just normal multiples, dcf etc for big pharma - as ultimately they are large businesses with cash flows) - biotech, maybe some kind of product NPV or probability weighted DCF?
2). Medical devices - also multiples/ dcf. anything specific on this one?
3). Services/ Hospitals (dcf) specific multiples ie. EV/ number of beds?
Generally am just trying to get some colour on how healthcare stuff is valued, and how it differs from the 'textbook' approaches to valuation. Also any comps adjustments that people normally make much appreciated for colour also.
Thanks a lot guys.
they don't really use any unique valuations methods that other groups wouldn't use. They do however use more tools in the toolkit as the healthcare sector is so diverse.
Probability weighted DCFs etc... your kidding. Nobody ever uses something that complicated. Please let me know if you've ever seen one at work.
Please don't talk about things you're not familiar with. Probability-weighted DCFs are definitely used in healthcare banking...specifically for biotech companies.
more than different valuation techniques, i think the primary difference is that healthcare will use different operating metrics when looking at companies in the industry. So, for example, for a private hospital operator, they would look at
ALOS (avg length of stay), in-patient & out-patient volume, procedure volume, etc...among many others.
But that is just one example. Someone in Healthcare Investment Banking, feel free to tell me I'm wrong :-)
as mentioned above, healthcare is an extremely diverse sector - the best way to figure out how to look at these industries is to find equity research if you can. I work for a large public PBM so I see deals range from specialty pharma to DME and other PBMs... and we haven't taken a similar approach to any two deals. take two specialty pharmacies for example, the therapeutic classes of each are obviously not going to be the same, some have preferred agreements with manufacturers, some may be more oncology focused, thus lower margins and some might be focused on slow growth, niche classes. that said, you obviously can't compare apples to apples across this industry. bottom line, there just isn't a standard for the industry.
on the banking side, you really wouldn't be digging too deep into the dcf, but getting an understanding of what the KPIs and drivers of each industry are is important. again, check out equity research for that. i've seen some weird models in my time but nothing to the extent of a probability weighted dcf/npv. i'm not sure that has been done in years, although i know it used to be very popular in biotech.
Thanks a lot guys this is helpful.
Also - does anybody know which 'branches' of healthcare make attractive LBO prospects? Have read about a few LBOs of care/nursing homes (i.e. Terrafirma buying Four Seasons in the UK). and would it be enough at interviews to just touch on the fact that nursing/care homes in this context make decent candidates for LBO because they've got pretty stable cash flows - and then go down the demographic route (ageing population underpinning Revenue growth and FCF generation for debt paydown)?
Thanks a lot.
As with any prospective LBO target, the company would have to have large, predictable cash flows that could support the debt load placed on it by the financial sponsor. Additionally, many players in the health care industry have relatively inelastic demand for their product. As long as those companies have a relatively predicable cost base, they might be attractive as well.
With all the boomers set to retire, long term care/nursing homes seem like they might fit that bill. I have a friend that works in the industry and they are defintely setting their sights on some pretty significant growth.
Thanks cdnbanker. could you very briefly explain to me how this works in practice ie weights applied through different stages of clin. trials and how terminal value is dealt with i.e. (growing perpetuity/ or whether an exit multiple is applied).
If you need equity research reports and industry primers on this industry, I have a few.
That would be extremely helpful mhurricane. Pls could you pm me with them. Much appreciated, thanks.
Biotech is ridonculous if you want quick and large gains, but you need a strong scientific background to distill the proof of concept behind novel compounds. There seems to be alot of guys in healthcare devices and services with business background tho.
Yeah, FDA/regulatory approval can make a stock jump 20+%. I've seen some go up 100%. Earlier this year, VRUS (Pharmasset) was acquired for an 85% premium by Gilead Sciences.
what couchy said it wrong - i used weighted valuation for pharma clients that have drugs in the pipeline pending fda approval. no other way to value them accurately enough if the drug hasn't been commercialized yet. It is the most widely used valuation method in biotech.
I'm sorry. I take back what I said. I interned 3 summers at one of the big healthcare buyside shops and never saw probability weighted dcfs.
With that said, when I went through training, they actually did teach me probabilit weighted valuation and real options valuation. I just never saw one outside of training
But overall in practice we used multiples and LBO / VC method valuation, which is pretty standard across most pe firms.
Well, if by buyside, you are referring to PE, that would make sense. Biotech companies don't exactly make great LBO candidates.
At a very high level, you are right. Probabilities are assigned to each phase of clinical trials, and a cumulative probability of success is calculated and applied to the future cash flows.
In terms of terminal value, it depends. You would consider the same factors you should always consider when building a DCF: What is the most likely exit scenario? If you think the target will be acquired, an exit multiple makes more sense. If you think it will continue to operate as a standalone company, you would use a perpetuity growth rate with a negative growth rate (due to patent expiry). In some cases, you would not consider terminal value at all (if your DCF time horizon is long and covers the entire patent-protected period), since the TV would be negligible anyways.
BB IBD Healthcare Super Day (Originally Posted: 01/13/2015)
Although it does seem obvious to know industry specifics, Healthcare is nonetheless an extremely broad field. I'll be sure to know about the recent M&A Boom, regulation reform, and recent deals, but what exactly should I focus on when attacking this super day? Overall, what industry questions do you think will be asked?
Also, what are the Healthcare valuation methods that I should know about (i.e. Sum-of-the-Parts, etc.) in addition to DCF, Comps, and Prec Trans?
Any advice on what I should bring to the table would be much appreciated.
http://www.wallstreetoasis.com/forums/healthcare-overview-part-1
Probably have your own opinion on where you think the Healthcare/Biotech/BP space is going in the future: Renewed focus on R&D? M&A with a continued focus on inversions?
Probably have an opinion on the costs/benefits of inorganic vs. organic growth so you sound intelligent and that you can display to your interviewer that you have a genuine intellectual interest in the field.
Maybe a stock pitch, you never know.
More importantly, have your behaviorals down pat. Why you want to work at that specific firm, why banking, why healthcare, etc. Make sure you don't bore them with your story and make yourself sound interesting and more hardworking than other candidates.
Thanks man, great advice. Silver Bananaed.
Re: BB Investment Banking Healthcare (Originally Posted: 10/07/2016)
In response to arcticrecon's request for active M&A advisors in the bio-tech/pharma space ... I couldnt figure out how attach the file to PM ...
Advisors in Column T
Occaecati quia eos et itaque harum magnam atque quo. Molestiae veritatis odit laudantium architecto.
Vel et molestias dolor. Non aut similique a pariatur fuga sed qui nihil. Delectus reprehenderit sint libero incidunt nam tempora qui. Ipsum omnis laboriosam laudantium ea qui suscipit. Aut dolorum autem facere enim perspiciatis eum.
Consequatur omnis aperiam quibusdam est delectus nam. Nostrum molestiae quidem odit occaecati omnis quis. Assumenda repellat beatae et qui maiores facilis eos. Odio aut praesentium et autem quas sunt odit. Libero nulla sed expedita quaerat sint. Officiis et nulla sit.
A nihil aut officiis expedita. Id error voluptatem est molestias eveniet accusamus maiores dicta. Tenetur mollitia voluptas illum quas odio eveniet nostrum tempora.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Suscipit impedit placeat qui fuga vitae dolore dignissimos. Et alias rerum commodi sed. Ullam voluptas nostrum atque eos cupiditate id sequi. Fugiat aut impedit consectetur provident autem.
Quam iste quia fugit non. Non doloribus quia voluptatem ut praesentium aut incidunt. Laboriosam quam qui consequatur cum incidunt voluptatem odit excepturi. Aliquam est magni inventore qui. Aut facere est ut dicta quo expedita.
Accusantium perferendis unde at iusto. In omnis aut sed.
Harum iusto aspernatur voluptas praesentium odio autem non sequi. Consectetur quaerat aperiam a optio in. Et eaque autem nihil dolor eius libero. Enim voluptatum sit tenetur natus eos voluptas quia. Harum beatae error magni eaque est occaecati itaque. Sequi deleniti sint fugit accusantium qui quia rem et. Distinctio ducimus iste quia ratione asperiores sed.